Loading
A phase 1 trial of Lunresertib run by Debiopharm International SA, now recruiting.
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT04855656 by Debiopharm International SA, with 464 participants planned, started 2021-04-30. Conditions recorded: Advanced Solid Tumor. Interventions recorded: Lunresertib, RP-3500 and Zedoresertib.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Debiopharm and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/